<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930640</url>
  </required_header>
  <id_info>
    <org_study_id>BL-PI-SGF200</org_study_id>
    <nct_id>NCT04930640</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of SGF200 on Immune Enhancement</brief_title>
  <official_title>A 8 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of SGF200 on Immune Enhancement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to investigate the efficacy and safety of SGF200 on immune&#xD;
      enhancement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 100&#xD;
      subjects were randomly divided into SGF200 group or placebo group. The investigators measured&#xD;
      Natural Killer cell activity, Cytokines(IL-2, IL-12, IFN-γ, TNF-α), questionnaire scores of&#xD;
      upper airway infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Actual">May 26, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Natural Killer cell activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Natural Killer cell activity was measured in study baseline and 8 week. A ratio of effector cell and target cell was 2.5:1, 5:1, 10:1&#xD;
(Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Cytokines</measure>
    <time_frame>8 weeks</time_frame>
    <description>For blood Cytokines analysis, collect 3 ml of blood in one SST tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes.&#xD;
Inspection item were IL-2, IL-12, IFN-γ, TNF-α.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Wisconsin Upper Respiratory Symptom Survey-21</measure>
    <time_frame>8 weeks</time_frame>
    <description>Wisconsin Upper Respiratory Symptom Survey-21 consists of seven steps, including individual symptoms, functional quality of life, and overall improvement. Find the sum of the symptom questions and give them the total score. Seek, sum up the questions of life, and get the total quality of life. The sum of the total score of symptoms and the total score of quality of life is also obtained.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>SGF200 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 1x10^9 CFU/day, GF101 200 U/day)]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)]</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SGF200 group</intervention_name>
    <description>1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week</description>
    <arm_group_label>SGF200 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 8 week</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women over 50 years&#xD;
&#xD;
          -  After fully hearing and fully understanding this clinical trials, those who agree to&#xD;
             voluntarily decide to participate and to comply with the notice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than&#xD;
             8000/㎕&#xD;
&#xD;
          -  Those who received influenza vaccination within 3 months before first intake for test&#xD;
             product&#xD;
&#xD;
          -  Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg&#xD;
             / m^2 at the screening&#xD;
&#xD;
          -  Those who have a clinically significant acute or chronic cardiovascular system,&#xD;
             endocrine system, immune system, respiratory system, liver biliary system, kidney and&#xD;
             urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic&#xD;
&#xD;
          -  Those who take a medication or health function food that affects your promotion of&#xD;
             immunity within 1 month prior to the screening&#xD;
&#xD;
          -  Those who have received antipsychotic medication within 3 months before screening&#xD;
&#xD;
          -  Those who alcoholic or drug abuse suspected&#xD;
&#xD;
          -  Those who participated in other clinical trials within 3 months before screening&#xD;
&#xD;
          -  Laboratory test by show the following results&#xD;
&#xD;
               -  Aspartate Transaminase(AST), Alanine Transaminase(ALT) &gt; Reference range 3 times&#xD;
                  upper limit&#xD;
&#xD;
               -  Serum Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Those who doesn't accept the implementation of appropriate contraception of a&#xD;
             childbearing woman&#xD;
&#xD;
          -  Principal Investigator judged inappropriate for participation in study because of&#xD;
             Laboratory test result, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Principal investigator, Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>SGF200</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

